Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

By D. Klonoff, John B. Buse, L. L. Nielsen, X. Guan, C. Bowlus, J. Holcombe, M. Wintle, D. Maggs. Current Medical Research and Opinion, 2008

751 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pharmacology, physiology, and mechanisms of incretin hormone action. (2013, background): “Exenatide (10 mg, twice daily) decreased ALT levels in subjects with T2DM (both male and female, A1C = 8.2% at start of therapy) in an uncontrolled, open-label study over a 3 year period (Klonoff et al., 2008).”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “Results from its 3-year follow-up showed that with exenatide (10 g b.i.d.), a reduction in HbA1c of 1.0% was sustained, with 46% achieving HbA1c of 7%, and reduction in body weight was progressive with weight loss of 5.3 kg at the end of 3 years of treatment (Klonoff et al., 2008).”
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, background): “5 years, and the decline in A1C was shown to persist (275).”